On December 15, 2023, Wave Life Sciences announced the initiation of dosing in their Phase 2 FORWARD-53 study, which is evaluating WVE-N531 as a treatment for boys with Duchenne muscular dystrophy (DMD) who are amenable to exon 53 skipping.
Please find more information in their Community Letter here.
